Olsen, Flemming Javier http://orcid.org/0000-0001-9511-8375
Landler, Nino Emanuel
Christensen, Jacob
Feldt-Rasmussen, Bo
Hansen, Ditte
Christoffersen, Christina
Ballegaard, Ellen Linnea Freese
Sørensen, Ida Maria Hjelm
Bjergfelt, Sasha Saurbrey
Seidelin, Eline
Bro, Susanne
Biering-Sørensen, Tor
Funding for this research was provided by:
Region Hovedstaden
Copenhagen University
Article History
Received: 31 January 2024
Accepted: 3 May 2024
First Online: 15 May 2024
Declarations
:
: D.H.: Steering Committee member of the Boehringer Ingelheim financed SHARP3 trial. Advisory Board: GSK. Lecture fee: Astra Zeneca and UCB Nordic. E.L.F.B.: Received non-related research grants from AstraZeneca. T.B-S.: Steering Committee member of the Amgen financed GALACTIC-HF trial. Primary investigator of the Sanofi Pasteur financed “NUDGE-FLU” trial. Primary investigator of the Sanofi Pasteur financed “DANFLU-1” trial. Primary investigator of the Sanofi Pasteur financed “DANFLU-2” trial. Steering Committee member of “LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System” trial. Steering Committee member of the Boehringer Ingelheim financed SHARP3 trial. Advisory Board: Sanofi Pasteur, Amgen, and GSK. Speaker Honorarium: Novartis, Sanofi Pasteur, GE Healthcare, and GSK. Research grants: GE Healthcare, AstraZeneca, Novo Nordisk and Sanofi Pasteur. The other authors declare no conflict of interest.